DDInter248 DDInter1082
Bumetanide is a sulfamyl diuretic.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Bumetanide {u} (Compound) resembles {v} (Compound) Indapamide
Bumetanide {u} (Compound) treats {v} (Disease) hypertension
Bumetanide {u} (Compound) binds {v} (Gene) CA12
Bumetanide {u} (Compound) palliates {v} (Disease) chronic kidney failure
Bumetanide {u} (Compound) is included by {v} (Pharmacologic Class) Increased Diuresis at Loop of Henle
Bumetanide {u} (Compound) downregulates {v} (Gene) COTL1
Bumetanide {u} (Compound) causes {v} (Side Effect) Blood uric acid increased
Bumetanide (Compound) resembles Indapamide (Compound)
Bumetanide (Compound) treats hypertension (Disease)
Bumetanide (Compound) binds CA12 (Gene)
Bumetanide (Compound) palliates chronic kidney failure (Disease)
Bumetanide (Compound) is included by Increased Diuresis at Loop of Henle (Pharmacologic Class)
Bumetanide (Compound) downregulates COTL1 (Gene)
Bumetanide (Compound) causes Blood uric acid increased (Side Effect)